UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

                                                Commission File Number 333-64420

(Check One): [ ] Form 10-K  [ ] Form 20-F  [ ] Form 11-K  [X] Form 10-Q
[ ]Form N-SAR   [ ]Form N-CSR

    For period ended March 31, 2003

    [ ]  Transition Report on Form 10-K

    [ ]  Transition Report on Form 20-F

    [ ]  Transition Report on Form 11-K

    [ ]  Transition Report on Form 10-Q

    [ ]  Transition Report on Form N-SAR

    For the transition period ended: ____________________

      Nothing in this form shall be construed  to imply that the  Commission has
verified any information contained herein.

      If the  notification  relates to a portion of the  filing  checked  above,
identify the item(s) to which the notification relates:

PART I-- REGISTRANT INFORMATION

                                  MEDICOR LTD.
                            (Full Name of Registrant)

                                 SCIENTIO, INC.
                           (Former Name if Applicable)

                         4560 S. Decatur Blvd., Ste. 300
         (Address of Principal Executive Office (Street and Number))

                             Las Vegas, Nevada 89103
                           (City, State and Zip Code)




PART II-- RULE 12b-25(b) AND (c)

If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)

        (a)   The reasons  described  in  reasonable  detail in Part III of this
              form  could  not be  eliminated  without  unreasonable  effort  or
              expense;

        (b)   The subject annual report,  semi-annual report,  transition report
              on Form 10-K,  20-F,  11-K or N-SAR, or portion  thereof,  will be
[X]           filed on or  before  the  fifteenth  calendar  day  following  the
              prescribed due date; or the subject quarterly report or transition
              report on Form 10-Q, or portion thereof will be filed on or before
              the fifth calendar day following the prescribed due date; and

        (c)   The  accountant's  statement  or other  exhibit  required  by Rule
              12b-25(c) has been attached if applicable.

PART III-- NARRATIVE

      State below in reasonable  detail the reasons why Forms 10-K,  11-K, 20-F,
10-Q, N-SAR, or the transition report portion thereof, could not be filed within
the prescribed time period.

          The Form  10-Q  could  not be filed  without  unreasonable  effort  or
     expense because of the recent reverse merger transaction with International
     Integrated   Incorporated,   a  British  Virgin  Islands  Company  and  the
     complications  and  difficulties  in merging the financial,  accounting and
     other  information of International  Integrated  Incorporated  with that of
     MediCor Ltd.

PART IV-- OTHER INFORMATION

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
notification

        Jim J. McGhan                   (702)        932-4560
        ----------------------------------------------------------------
        (Name)                      (Area Code) (Telephone Number)

(2) Have all other  periodic  reports  required under Section 13 or 15(d) of the
Securities  Exchange Act of 1934 or Section 30 of the Investment  Company Act of
1940  during  the  preceding  12  months  or for such  shorter  period  that the
registrant  was  required to file such  report(s)  been filed?  If answer is no,
identify report(s).

                                [ ]  Yes        [X] No

          Amendment  to  Current  Report on Form 8-K dated  February  7, 2003 to
     include audited and pro forma financial information.

(3) Is it anticipated  that any significant  change in results of operations for
the  corresponding  period for the last  fiscal  year will be  reflected  by the
earnings statements to be included in the subject report or portion thereof?

                                [X]  Yes        [ ] No

                                  MEDICOR LTD.

      Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

    Date:  May 15, 2003                  By:  /s/ Jim J. McGhan
                                             ----------------------
                                              Jim J. McGhan
                                              Chief Operating Officer